| Day One26 October
2010 |
|
| 08:25 |
|
| 08:30 |
Creative Ways to Address Unmet Medical Needs and Business Demands |
Addressing unmet clinical needs through collaboration, speed and understanding
- Success and challenges in the indications discovery effort
- Developing an indications discovery effort
- Making a commercially attractive business case
- Orphan drug development - opportunities for wider indications
Dean Welsch,
Research Fellow, Indications Discovery,
Pfizer Global Research & Development
USA
|
|
| 09:00 |
Personalised Health Care Strategies
|
Improving decision making with biomarker discovery and assay development tools
- Improved decision making with R&D tools for profiling targets, compounds
- Understanding pathways and mechanisms for patient subpopulations and optimised patient stratification
- Implementation pharmacodiagnostic development early for increased benefit/risk ratio
- Companion diagnostics
Dr. Gerd Maass,
Global Head of Biomarker and Pathway Analysis,
Roche Pharma Research and Early Development
|
|
| 09:30 |
| Target Identification and Validation |
Target validation – the key factor for future success in pharma R&D
- Translating and establishing operational excellence from the target validation point of view to increase efficacy and profitability during drug discovery
- Adopting multi layer approaches to discharge any unexpected challenges
- Exploring new tools and gaining control on gene expression to successfully accomplish a multi disciplinary approach
Dr. Lorenz Mayr,
Executive Director Unit Head Biology, Protease Platform,
Novartis Pharma AG / NIBR
Switzerland
|
|
|
| Lead Identification and Optimisation |
|
|
Influence of drug like concepts in early decision making
- Which drug like properties can better influence early decision making to ensure success?
- Evaluating early portfolios and application of drug discovery processes
- Probabilistic approaches to filter out poor players and reduce pipeline attrition - extending Lipinksi’s rule of 5
- Using ligand efficiency metrics
- Compound management strategies - reducing lipophilicity and improving safety profiles
-
Dr. Paul Leeson,
Director of Medicinal Chemistry,
Astra Zeneca
UK
|
|
|
| Research Alliances and Collaborations |
|
|
Successful lead generation with lucrative research alliances - setting up lean collaborations with biotech and small molecule players
- Agreeing early licensing deals - sharing risks and rewards
- Offering free capacity to partners to develop pre-clinical candidate status and developing early alliances
- Harnessing complementary skills
- Taking over lead candidates in and at a later stage develop in return for milestone royalties
- Expanding therapeutic focus and smarter combination for drugs increase likelihood for
-
Dr. Mathias Schmidt.,
Associate Principal, Head of Early Alliance Team,
Nycomed GmbH
|
|
|
| Informatics, Data and Knowledge Management |
Managing the world’s largest Medicine cabinet - enabling technologies to drive the efficiency and effectiveness of the drug discovery process
- Maximising the value of the Pfizer’s investment in the compound file
- Effective technologies to store and provision the compound file
- Making effective changes and investments improve our utilization of the compound file
- Overcome to implementation challenges
- Successfully applying continuous Improvement methodologies in this domain
Jerry Lanfear,
Head of Materials and Data Management World-Wide Research and Development ,
Pfizer Ltd
UK
|
|
|
|
| 10:10 |
| New Targets in Inflammation and Metabolic Disorders and Cancer |
- Validating the target for a specific indication
- How to handle the selection of a specific indication when you have the benefit of working with one of the best examples of a multi-diseases target
- How to advance few compounds in different indications linked to the same target
Dr.Giuseppe Biondi ,
R&D Director ,
Angelini-Santa Palomba Research Center
Italy
|
|
|
| Candidate Development Strategies |
Targeting transcription factors with small molecules: from the druggable to the undruggable
- Have we fully explored the chemical space and utilities for small molecules? Exploring new and promising avenues
- Directing explorations of chemical space towards compounds with the greatest biological relevance
- Exploring novel chemical space with computational and structural biology
- Expanding druggable chemical landscapes including target space historically perceived as undruggable
- Virtual screening partnered with structural biology - X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy and/or rigorous homology modeling
- Cheaper, streamlined ways to identify hits and validating leads prior to preclinical and clinical evaluation
Dr. Alan C Rigby,
Director Program in Drug Discovery and Target Validation,Center for Vascular Biology Research ,
Harvard Medical School
USA
|
|
|
| Achieving Clinical Advancement |
Faster pre-clinical development of a lead compound -achieving clinical advancement
- Resolving issues quickly for clinical advancement
- Achieving early decision making
-
- Reducing time to clinic
Dr. Ming Wang,
Director Research,
Amgen
USA
|
|
|
| Lead Discovery Informatics |
- Virtual screening strategies
- Implementing a lead discovery informatics programme
Dr Andreas Bender,
Lecturer for Molecular Informatics,
University of Cambridge, Unilever Centre for Molecular Science Informatics
|
|
|
|
| 10:50 |
Pre-scheduled one-to-one meetings |
|
|
|
| 12:10 |
| Spectacular Targets for Orphan Diseases and Larger Patient Populations |
Identifying spectacular targets for orphan disease and larger patient populations
- Understanding how a chain of genes may be the root of several diseases
- Ensuring rock solid biochemical rationale at the onset - maximising opportunities for extra indications
- Identifying molecular similarities and pathways between different diseases
- Quicker, cheaper innovative new drugs - presenting a commercially attractive business case for parallel drug development
- Developing valuable antibodies and small molecule drugs
- Risk reward ratio's - achieving cheaper regulatory filings and extra revenue through repositioning strategies
Dr. Georg C. Terstappen PhD, adj. Prof.,
,
University of Siena
Italy
|
|
|
| Small Molecules and Biologics vs. Sirna, Stem Cells and Gene Therapy |
Which approach will lead to increased productivities?
- How can the industry further develop new therapeutic approaches?
- Balancing between pure outright disruptive technologies and novelty vs. sticking to well proven strategies
- Exploring the chemical space and utilities for small molecules
Dr. Barry Morgan,
Vice President, Molecular Discovery Research,
GlaxoSmithKline
USA
Dr. Ron Swanson,
Senior Director,
Johnson & Johnson
USA
Dr. Denise Karaoglu ,
Senior Principle Scientist and Research Fellow,
Abbott Laboratories
USA
Prof. Andreas Baumann,
Global Early Development,
Bayer Schering Pharma AG,
Germany
|
|
|
| Understanding Better Pathophysiological Disease Models to Improve Tox Studies |
Increasing predictivity in toxicological studies
- Understanding the pathophsiology of human disease states and translating this to animal models
- Improving the relevance of animal models in pre-clincial toxicology studies
- Enhancing the chances of successfully predicting clinical adverse effects during pre-clinical development
Dr. Josef Scheiber,
In Silico Sciences - Bioinformatics, Pharma Research Penzberg ,
Roche Diagnostics GmbH
|
|
|
| Novel Computational Approaches to Biomolecular Knowledge Mining |
Using new methods to integrate and mine molecular data for translational systems research
- Combining information from genome-scale experiments
- Developing visualisation tools for integrative data analysis
- Leveraging functional annotations and network data
- Prioritising potential disease and drug targets
Dr. Mario Albrecht,
Group Leader for Molecular Networks in Medical Bioinformatics ,
Max Planck Institute for Informatics
Germany
|
|
|
|
| 12:50 |
| Disease Systems Chemical Biology |
|
|
A way to link drug action and disease susceptibility
Prof. Olivier Taboureau,
Center for Biological Sequence Analysis, DTU Systems Biology ,
Technical University of Denmark
Denmark
|
|
|
| Strategies for Shaping a Screening File for Lead Discovery |
Dr. Jeremy Everett,
Director Medicinal Chemistry,
|
|
|
| External Collaboration for Pre-Clinical Development |
|
|
Creating smaller decision making groups and network alliances
- Breaking down decision making groups
- Creating different skills and tensions
- Establishing a network of alliances - emulating small, innovative biotech companies
- Building and establishing networks
-
Dr. Andrew Parsons,
VP Pre-clinical Development, CEED,
GSK
UK
|
|
|
| Using Informatics to Enable Decision Making |
Cutting and slicing data and delivering consolidated reports throughout the business (Thompson Reuters client case study)
- Enabling better decision making
Dr. Andreas Mattern,
,
|
|
|
|
| 13:25 |
|
| 14:25 |
| Virtual Screening Workshop |
Virtual high throughput screening to accelerate lead identification and optimisation
- Optimising the compound library for HTS through in silico modelling - reducing time and resources needed for HTS
- Improving docking and in silico screening models to improve accuracy of HTS
- Can virtual screening replace HTS as the standard method of candidate selection?
- Virtual screening, structural biology, X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy and rigorous homology modeling
|
|
|
| Interactive Workshop Led by Nuevolution |
Fragment based lead discovery using millions to billions of screening compounds
- Nuevolution’s proprietary Chemetics® technology brings Fragment Based Lead Discovery to the billion compound library scale using standard laboratory equipment.
- Tens of thousands of diverse fragments, which are made to react with tens of thousands of fragments provides access to truly diverse libraries that makes the difference for lead discovery.
- Each compound within a Chemetics® library is linked to a strand of DNA encoding the synthetic history and the chemical structure of the small-molecule.
- DNA offers a unique opportunity for storage of information and single-molecule detection.
- In few days, screening libraries comprising hundreds of millions of synthetic molecules may be screened by one person using micrograms of target material and nanograms of library material.
- The Chemetics® approach to small molecule lead discovery has proved to be successful for multiple types of targets including protein-protein interactions.
Alex Haahr Gouliaev,
Chief Executive Officer,
Nuevolution A/S
Denmark
|
|
|
| Drug Development Decisions Workshop |
FDA drug approval packages and drug development decisions: New Avenues for supporting strategic decision-making
Albert van der Wal,
Senior Product Sales Manager,
Elsevier
|
|
|
|
| 15:05 |
Pre-scheduled one-to-one meetings |
|
|
|
| 16:35 |
| Lead Identification: Generating Value, Addressing Attrition |
Design, synthesis and selection of DNA-encoded small-molecule libraries
- Using DNA encoding to select hundreds of millions of discrete molecules in a single container with minimal amounts of protein
- HT sequencing techniques to deconvolute selection output to yield families of ligands and emerging trends of SAR and selectivity before biochemical assay
- Using rapid and inexpensive routes to the discovery of small-molecule drug leads
- How does DNA encoding compare to conventional high throughput screening?
- Achieving favourable process economics
Dr. Barry Morgan,
Vice President, Molecular Discovery Research,
GlaxoSmithKline
USA
|
|
|
| Transforming Discovery & Development of Human Monoclonal Antibodies |
- SIMPLE ANTIBODY™ technology exploits active immunization of Camelids
- V regions of conventional Camelid antibodies have high human sequence homology
- CDRs of these V regions show perfect human structural homology
- Outbred nature of Camelids provides high diversity of functional antibodies upon immunization with a human disease target
- Active immunization yields very high affinity antibodies (10E-4 to 10E-5 off rates translating into picomolar affinities / potencies)
Dr. Prof. Hans de Haard,
Chief Scientific Officer,
arGEN-X BV
Belgium
|
|
|
| Novel Models of Idiosyncratic Toxicity |
Drug-induced mitochondrial dysfunction yields a novel model of idiosyncratic toxicity
Dr. Jim Dykens,
Associate Research Fellow, Drug Safety R&D,
Pfizer
|
|
|
|
| 17:15 |
Keynote session: Continuous Improvement and Systems Biology |
Dr. Andrew Seddon,
Senior Director Strategic Managment Group,
Pfizer Global Research & Development
USA
|
|
| 17:50 |
Chairman's closing remarks and drinks reception |
|
|
|
|